Edition:
India

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

84.82EUR
23 May 2018
Change (% chg)

€-0.06 (-0.07%)
Prev Close
€84.88
Open
€84.70
Day's High
€85.20
Day's Low
€83.34
Volume
323,534
Avg. Vol
427,104
52-wk High
€98.82
52-wk Low
€61.88

Select another date:

Wed, May 2 2018

BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients

* DGAP-NEWS: MORPHOSYS AND GALAPAGOS ANNOUNCE INITIATION OF THE IGUANA PHASE 2 CLINICAL TRIAL WITH MOR106 IN ATOPIC DERMATITIS PATIENTS

BRIEF-Galapagos Presents Strong Disease-Modifying Effects With Glpg1972 At Oarsi 2018

* REG-GALAPAGOS PRESENTS STRONG DISEASE-MODIFYING EFFECTS IN PRECLINICAL MODEL OF OSTEOARTHRITIS WITH GLPG1972 AT OARSI 2018

BRIEF-Galapagos Q1 Operating Loss Widens To 32.0 Million Euros

* Q1 REVENUE EUR 44.8 MILLION VERSUS EUR 39.9 MILLION YEAR AGO

BRIEF-Galapagos NV Q1 Basic And Diluted Loss Per Share EUR 0.73

* GALAPAGOS EXPECTS AN OPERATIONAL CASH BURN BETWEEN €220 AND €240 MILLION IN 2018

BRIEF-Galapagos NV Creates New Warrant Plan

* BOARD OF DIRECTORS CREATED 1.6 MILLION WARRANTS UNDER NEW WARRANT PLANS

BRIEF-Galapagos Announces ISABELA Phase 3 Program In IPF

* ANNOUNCES THE DESIGN OF A WORLDWIDE PHASE 3 PROGRAM, TO EVALUATE GLPG1690 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

BRIEF-Galapagos Announces Isabela Phase 3 Program In IPF

* ANNOUNCES DESIGN OF A WORLDWIDE PHASE 3 PROGRAM TO EVALUATE GLPG1690 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

BRIEF-Galapagos FY Net Result Swings To Loss Of 115.7 Million Euros

* REPORTED ON THURSDAY FY NET LOSS OF €115.7 MILLION, COMPARED TO NET PROFIT OF €54.0 MILLION IN 2016

BRIEF-Morphosys And Galapagos Present Results From Phase 1 Study With Mor106

* SAID ON SATURDAY MORPHOSYS AND GALAPAGOS PRESENT RESULTS FROM A PHASE 1 STUDY WITH MOR106 IN ATOPIC DERMATITIS AS LATE-BREAKING ABSTRACT

BRIEF-Galapagos And MorphoSys Present Results From Phase 1 Study With MOR106 In Atopic Dermatitis

* GALAPAGOS AND MORPHOSYS ANNOUNCED ON SATURDAY THAT MOR106 WAS GENERALLY WELL TOLERATED IN ATOPIC DERMATITIS (AD) PATIENTS

Select another date: